十二指肠黏膜重塑:概念验证、操作开发及临床初步应用
研究开发了微创内镜下热水消融的十二指肠黏膜重塑术(DMR),用于治疗胰岛素抵抗相关代谢病。大鼠假手术对照实验显示十二指肠黏膜擦除使高血糖平均降低59 mg/dL(P<.05),猪实验证实操作安全且6周黏膜完全愈合。首次人体开放标签研究显示无穿孔、胰腺炎或出血,术后3个月黏膜完全再生,血糖和肝脏指标改善持续至6个月随访。
要点
- 大鼠实验:十二指肠黏膜擦除使高血糖平均降低59 mg/dL,假手术组较基线无变化(P<.05)。
- 首次人体研究:DMR操作成功,无穿孔、胰腺炎或出血,术后3个月黏膜完全再生。
- 血糖和肝脏指标改善持续至6个月随访,DMR有望成为2型糖尿病的内镜干预手段。
核心结论
- DMR作为一种内镜干预手段,在2型糖尿病患者中显示出改善血糖和肝脏参数的潜力。
- 作者表示正在开展进一步机制和临床研究,以探索DMR作为代谢病治疗的方法。
研究设计与样本
- 研究包括大鼠假手术对照概念验证研究、猪纵向安全性研究,以及开放标签首次人体安全性和有效性研究。
- 首次人体研究纳入2型糖尿病患者,评估DMR的安全性和有效性。
主要发现
- 大鼠实验中,十二指肠黏膜擦除使高血糖平均降低59 mg/dL,假手术组较基线无变化(P<.05)。
- 猪实验中,球囊导管成功且安全地将热水消融递送至十二指肠黏膜和浅层黏膜下层,第6周时黏膜完全愈合。
- 首次人体研究中,热水消融成功实施,无穿孔、胰腺炎或出血的证据;术后3个月十二指肠活检显示黏膜完全再生,未见炎症,部分消融部位活检标本可见轻微至轻度胶原带沉积,无纤维化瘢痕证据。
- 血糖和肝脏指标改善持续至6个月随访。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: We aimed to develop duodenal mucosal resurfacing (DMR), a minimally invasive upper endoscopic hydrothermal ablation procedure, to treat insulin-resistant metabolic diseases. METHODS: We completed a sham-controlled, rodent proof-of-concept study and longitudinal safety study in pigs to demonstrate feasibility to test DMR in humans. Subsequently, the DMR procedure was implemented in an open-label first-in-human (FIH) study of safety and efficacy in patients with type 2 diabetes (T2D). RESULTS: In rats, duodenal abrasion reduced hyperglycemia by 59 mg/dL on average, compared with no change from baseline in the sham treatment arm (P < .05). In pigs, the balloon catheter successfully and safely delivered hydrothermal ablation to the duodenal mucosa and superficial submucosa. Complete mucosal healing was demonstrated by week 6. In the FIH study, hydrothermal ablation was successfully administered with no evidence of perforation, pancreatitis, or hemorrhage. Duodenal biopsy specimens obtained 3 months postprocedure demonstrated full mucosal regrowth. No inflammation was observed, and there was minimal-to-mild collagen banding deposition observed in a proportion of ablation site biopsy specimens with no evidence of fibrotic scarring. Glycemic and hepatic measures improved through 6 months of follow-up. CONCLUSIONS: DMR shows potential as an endoscopic intervention that improves glycemic and hepatic parameters in patients with T2D. Further mechanistic and clinical studies are underway to further explore DMR as a treatment for metabolic disease.
引用
- Haidry RJ, van Baar AC, Galvao Neto MP, et al. Duodenal mucosal resurfacing: proof-of-concept, procedural development, and initial implementation in the clinical setting. Gastrointest Endosc. 2019. PMID: 30935932. doi:10.1016/j.gie.2019.03.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。